BMY — Bristol-Myers Squibb Co Cashflow Statement
0.000.00%
Last trade - 00:00
- $99.61bn
- $145.40bn
- $45.01bn
- 67
- 64
- 72
- 75
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 3,460 | -8,995 | 7,014 | 6,345 | 8,040 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 720 | 10,701 | 1,153 | 1,412 | 1,262 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 3,065 | 983 | -1,253 | -2,229 | -1,914 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 8,067 | 14,052 | 16,207 | 13,066 | 13,860 |
Capital Expenditures | -836 | -753 | -973 | -1,118 | -1,209 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -8,934 | -10,106 | 435 | 56 | -1,086 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -9,770 | -10,859 | -538 | -1,062 | -2,295 |
Financing Cash Flow Items | -53 | 542 | 641 | 984 | 27 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 7,621 | -1,151 | -16,224 | -16,962 | -9,416 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 5,909 | 2,153 | -657 | -4,991 | 2,194 |